Clinical trials in Bad Oeynhausen – page 15

329 clinical trials in Bad Oeynhausen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Bad Oeynhausen at a glance

329

clinical trials

Research sites1

Quick filters

329 trials in Bad Oeynhausen

Open in trial search

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:GSK5733584
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Norwegian University Of Science And Technolology

Contact Research Centre

Acute lymphocytic leukaemia

Not yet recruiting

Study of blinatumomab plus drug combination in children and adolescents with acute lymphoblastic leukemia

Registered drugNo placebo

Study of blinatumomab plus drug combination in children and adolescents with acute lymphoblastic leukemia

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Asparaginase
Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Contact Research Centre

Colorectal cancer metastatic

Not yet recruiting

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Type 2 diabetes mellitus

Not yet recruiting

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Insulin degludec
Sponsor:Novo Nordisk A/S

Contact Research Centre

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Carboplatin
Sponsor:GPOH gGmbH

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Hypertrophic cardiomyopathy

Not yet recruiting

Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Investigational

Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Mavacamten
Sponsor:Myokardia Inc.

Contact Research Centre

Schizoaffective disorder+2

Not yet recruiting

Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

Registered drugNo placebo

Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Amisulpride
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Bipolar disorder

Not yet recruiting

Study on the Effect of Citalopram, Sertraline, and Lithium for Patients with Bipolar Depression After First-Line Treatment Failure

Registered drugNo placebo

Study on the Effect of Citalopram, Sertraline, and Lithium for Patients with Bipolar Depression After First-Line Treatment Failure

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Citalopram
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Chronic kidney disease-associated pruritus

Not yet recruiting

Evaluation of MC2-25 Cream for Itching in Patients with Chronic Kidney Disease-associated Pruritus

Investigational

Evaluation of MC2-25 Cream for Itching in Patients with Chronic Kidney Disease-associated Pruritus

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Mc2 Therapeutics Limited

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:GPOH gGmbH

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Bad Oeynhausen

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials exploring treatments for heart failure and cardiovascular disease, including studies of novel compounds like baxdrostat and pelacarsen to reduce major cardiovascular events.

Heart Failure Prevention
Coronary Artery Disease
Cardiomyopathy Management

Advanced diagnostic approaches including PET imaging for coronary conditions.

02 Metabolic Disorders

Comprehensive research focusing on Type 2 Diabetes management and its complications, including studies on innovative treatments for diabetic peripheral neuropathy.

Diabetes Management
Cholesterol Control
Obesity Treatment

Novel therapeutic approaches for hypercholesterolemia and weight management.

03 Renal Studies

Ground-breaking research in chronic kidney disease treatment, particularly focusing on complications associated with diabetes and hypertension.

Acute Kidney Injury
Chronic Kidney Disease
Renal Protection

Innovative therapies targeting kidney function preservation and disease progression.

04 Specialized Cardiac Care

Advanced research in hypertrophic cardiomyopathy and cardiac structural conditions, including maternal-fetal cardiac development studies.

Atrial Fibrillation
Acute Myocardial Infarction
Congenital Heart Conditions

Targeted therapies for specific cardiac conditions and preventive interventions.

Back to Germany All countries